M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

Open Menu Close Menu

Dosage and administration for M-M-R^®_II (Measles, Mumps, and Rubella Virus Vaccine Live)

Dosage schedule for M-M-R^®_II

M-M-R^®_II offers health care providers like you a dosing regimen to help protect children against measles, mumps, and rubella.

1st Dose^a

12-15 months of age

2nd Dose^b

4-6 years of age

^aChildren who received an initial dose of MMR vaccine prior to their first birthday should receive additional doses of vaccine at 12–15 months of age and at 4–6 years of age to complete the vaccination series.¹

^bSecond dose may be administered prior to 4 years of age, provided that there is a minimum interval of one month between the doses of MMR vaccine, live.¹

Flexible Route of Administration

A single-dose of M-M-R^®_II is approximately 0.5 mL. It is administered intramuscularly or subcutaneously.

Not actual administration of M-M-R^®_II. For Illustration purposes only.

You have the option to choose to administer all routinely recommended injectable pediatric vaccinations included in the CDC immunization schedule, via the same IM route when you choose M-M-R^®_II as your measles, mumps, and rubella vaccine.^1-7

Method of Administration

M-M-R^®_II continues to be latex free.

Brands mentioned are trademarks of their respective owners.

References

Recommended child and adolescent immunization schedule for ages 18 or younger, United States, 2025. Updated October 7, 2025. Accessed October 22, 2025. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
Centers for Disease Control and Prevention (CDC). Administer the Vaccine(s). Last reviewed June 24, 2025. Accessed September 29, 2025. https://www.cdc.gov/vaccines/hcp/administration/during.html
Wolicki J, Miller E. Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book). 14th edition. Chapter 6: Vaccine administration. Centers for Disease Control and Prevention. Last reviewed April 8, 2024. Accessed October 22, 2025. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-6-vaccine-administration.html
PRIORIX. Prescribing Information. GSK; 2024.
SPIKEVAX. Prescribing Information. Moderna; 2025.
NUVAXOVID. Prescribing Information. Sanofi; 2025.
COMIRNATY. Prescribing Information. Pfizer; 2025.

Indications and Usage

M-M-R^®_II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.

The first dose of M-M-R^®_II is administered at 12 to 15 months of age and the second dose of M-M-R^®_II is administered at 4 to 6 years of age.

Selected Safety Information

M-M-R^®_II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.

Due caution should be employed in administration of M-M-R^®_II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.

Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.

Immune globulins (IG) and other blood products should not be given concurrently with M-M-R^®_II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.

The following adverse reactions have been identified during both the subcutaneous and intramuscular use of M-M-R^®_II or its components in clinical trials or reported during post-approval use: fever, rash, and injection-site reactions.

The following adverse reactions have been identified during the subcutaneous use of M-M-R^®_II or its components in clinical trials or reported during post-approval use: headache, dizziness, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.